BioCentury
ARTICLE | Product Development

To ensure global access to remdesivir, Gilead building coalition spanning South Asia, Europe and the UN

BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.

May 6, 2020 1:09 AM UTC

Gilead provided a glimpse Tuesday into how it plans to get remdesivir to patients around the globe in a way that’s both affordable and accessible by building a manufacturing consortium, granting licenses to South Asian generics companies and partnering with the Medicines Patent Pool and UNICEF.

Gilead Sciences Inc. (NASDAQ:GILD) has yet to name any manufacturing partners for the COVID-19 therapy...

BCIQ Company Profiles

Gilead Sciences Inc.